Search results

1 – 4 of 4
Per page
102050
Citations:
Loading...
Access Restricted. View access options
Article
Publication date: 4 July 2018

Hamed Kord Varkaneh, Somaye Fatahi, Somaye Tajik, Jamal Rahmani, Meysam Zarezadeh and Sakineh Shab-Bidar

Studies investigating the association between dietary inflammatory index (DII) and body mass index (BMI) have led to inconsistent findings. Therefore, to decisively conclude, this…

597

Abstract

Purpose

Studies investigating the association between dietary inflammatory index (DII) and body mass index (BMI) have led to inconsistent findings. Therefore, to decisively conclude, this paper aims to clarify the relationship between DII and obesity by performing meta-analysis.

Design/methodology/approach

PubMed, Scopus and Google Scholar were searched up to July 2017 using key words selected from Medical Subject Headings and other related keywords to identify all relevant articles. In total, 22 articles were entered into the meta-analysis; 22 studies compared the mean of BMI among subjects with highest versus the lowest DII and 4 studies had data on the hazard risk (HR) or odds ratio (OR) for obesity.

Findings

A meta-analysis on included studies indicated a significant association on either mean differences (MD) in BMI (MD = 0.811; 95 per cent CI: 0.365-1.256; p: 0.0001) or obesity OR (OR: 1.310; 95 per cent CI: 1.144-1.500; p = 0.000) by comparing the highest and lowest DII categories. Between-study heterogeneity was high (Cochrane Q test, p < 0.001, I2 = 98.1 per cent, df = 21, τ2 = 0.9273), and only dietary assessment methods could explain the source of heterogeneity in which 24-h dietary recalls were homogeny (I2 = 8.4 per cent, df = 2, p = 0.335).

Originality/value

The results of the present meta-analysis suggest that adherence to high DII score increased BMI and obesity. More prospective studies in different populations are needed to better clarify this relation.

Details

Nutrition & Food Science, vol. 48 no. 5
Type: Research Article
ISSN: 0034-6659

Keywords

Access Restricted. View access options
Article
Publication date: 23 November 2020

Somaye Fatahi, Fahime Haghighatdoost, Bagher Larijani, Pamela J. Surkan and Leila Azadbakht

Recent research has suggested the beneficial effects of omega-3 fatty acids on kidney function; however, differences in these benefits have not been well-documented with respect…

113

Abstract

Purpose

Recent research has suggested the beneficial effects of omega-3 fatty acids on kidney function; however, differences in these benefits have not been well-documented with respect to different omega-3 fatty acid sources. Hence, the purpose of this study is to compare the effects of plants, marine sources of omega-3 fatty acids and their combination on biomarkers of renal function in overweight and obese individuals.

Design/methodology/approach

Ninety-nine overweight and obese women from a weight loss clinic received three weight-reducing diets with fish (300 g/week), walnuts (18 walnuts/week) or fish + walnuts (150 g fish + 9 walnuts/week) for 12 weeks. Serum biomarkers of renal function were measured at the beginning and the end of the intervention.

Findings

After 12 weeks, a reduction in serum creatinine was statistically higher for both the fish + walnut (−0.16 ± 0.09 mg/dL, p = 0.001) and walnut (−0.15 ± 0.05 mg/dL, p = 0.001) diets compared with the fish diet (−0.05 ± 0.04 mg/dL). A significant decrease was seen in blood urea nitrogen (BUN) level in the fish + walnut group (−0.12 ± 0.05 mg/dL, p = 0.03) and walnut group (−0.10 ± 0.04 mg/dL, p = 0.03) compared to the fish group (−0.05 ± 0.03 mg/dL). The effect of serum creatinine and BUN in the fish + walnut diet group was relatively higher than in the walnut diet group. Also, a significant difference was observed regarding weight loss in the fish + walnut diet (−7.2 ± 0.9 kg, p = 0.03) compared to in the other groups. The change in other indices was not different among the three diets.

Originality/value

This study found synergistic benefits of the plant and marine omega-3 fatty acids in reducing serum creatinine, BUN and weight compared with isolated marine omega-3s in overweight and obese women.

Details

Nutrition & Food Science , vol. 51 no. 5
Type: Research Article
ISSN: 0034-6659

Keywords

Access Restricted. View access options
Article
Publication date: 28 August 2019

Hamed Kord-Varkaneh, Ammar Salehi-Sahlabadi, Seyed Mohammad Mousavi, Somaye Fatahi, Ehsan Ghaedi, Ali Nazari, Maryam Seyfishahpar and Jamal Rahmani

The authors performed a systematic review and meta-analysis of all published randomized controlled trials with the aim to determine and quantify the anti-hyperglycemic effects of…

105

Abstract

Purpose

The authors performed a systematic review and meta-analysis of all published randomized controlled trials with the aim to determine and quantify the anti-hyperglycemic effects of glutamine (Gln) in acute and chronic clinical settings.

Design/methodology/approach

The authors conducted a comprehensive search of all randomized clinical trials performed up to December 2018, to identify those investigating the impact of Gln supplementation on fasting blood sugar (FBS), insulin levels and homeostatic model assessment-insulin resistance (HOMA-IR) via ISI Web of Science, Cochrane library PubMed and SCOPUS databases. A meta-analysis of eligible studies was conducted using random effects model to estimate the pooled effect size. Fractional polynomial modeling was used to explore the dose–response relationships between Gln supplementation and diabetic indices.

Findings

The results of the present meta-analysis suggest that of Gln supplementation had a significant effect on FBS (weighted mean difference (WMD): –2.868 mg/dl, 95 per cent CI: –5.467, –0.269, p = 0.031). However, the authors failed to observe that Gln supplementation affected insulin levels (WMD: 1.06 units, 95 per cent CI: –1.13, 3.26, p = 0.34) and HOMA-IR (WMD: 0.001 units, 95 per cent CI: –2.031, 2.029, p = 0.999). Subgroup analyses showed that the highest decrease in FBS levels was observed when the duration of intervention was less than two weeks (WMD: –4.064 mg/dl, 95 per cent CI: –7.428, –0.700, p = 0.01) and when Gln was applied via infusion (WMD: –5.334 mg/dl, 95 per cent CI: –10.48, 0.17, p = 0.04).

Originality/value

The results from this meta-analysis show that Gln supplementation did not have a significant effect on insulin levels and HOMA-IR. However, it did significantly reduce the levels of FBS, obtaining a higher effect when the duration of the intervention period was less than two weeks.

Details

Nutrition & Food Science , vol. 50 no. 1
Type: Research Article
ISSN: 0034-6659

Keywords

Access Restricted. View access options
Article
Publication date: 26 September 2018

Somaye Fatahi, Hamed Kord Varkaneh, Alireza Teymouri and Leila Azadbakht

Clinical evidence has suggested that alpha-lipoic acid (ALA), a potent antioxidant, seems to have some effects on inflammatory process. However, these results are equivocal. The…

71

Abstract

Purpose

Clinical evidence has suggested that alpha-lipoic acid (ALA), a potent antioxidant, seems to have some effects on inflammatory process. However, these results are equivocal. The purpose of this paper is to investigate the nature of association between ALA and serum C-reactive protein (CRP) level by pooling the results from clinical trial studies.

Design/methodology/approach

Relevant studies were identified by systematic literature search of PubMed/MEDLINE, Scopus, Web of Sciences and Cochrane library up to September 2016 for randomized controlled trials (RCTs) evaluating the impact of ALA supplementation on CRP. The pooled data were summarized as weighted mean difference (WMD) and 95 per cent confidence interval (CI). Effect sizes of eligible studies were pooled using random- or fixed-effects (the DerSimonian–Laird estimator) depending on the results of heterogeneity tests.

Findings

Of 212 papers, 15 were eligible RCTs according to inclusion criteria. The selected studies comprised 1,408 cases and 457 controls. The dose of ALA supplement ranged from 300 to 1,200 mg, and the duration of follow-up was from 1 to 48 weeks. ALA supplementation significantly reduced the levels of circulating CRP (WMD: −0.088, 95 per cent CI: −0.131, −0.045, p < 0.001) with significant heterogeneity (I2 = 73.4 per cent, p < 0.001). Populations with age younger than 50 years (PMD: −0.060 mg/dl), receiving doses less than 600 mg/day (PMD: −0.057 mg/dl), having cardiovascular disease (PMD: −0.105 mg/dl), hemodialysis (PMD: −0.209 mg/dl), diabetes (PMD: −0.021 mg/dl) and otherwise healthy subjects (PMD: −0.045 mg/dl) were sources of heterogeneity.

Originality/Value

This meta-analysis of RCTs suggests that ALA supplementation seems to significantly reduce circulating CRP level.

Details

Nutrition & Food Science, vol. 48 no. 6
Type: Research Article
ISSN: 0034-6659

Keywords

1 – 4 of 4
Per page
102050